A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Preliminary Efficacy Study of IC14 in Acute Respiratory Distress Syndrome
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Atibuclimab (Primary)
- Indications Respiratory distress syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Implicit Bioscience
- 12 Mar 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 May 2018 Planned initiation date changed from 1 Jun 2017 to 1 Jun 2019.
- 13 Jan 2017 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.